Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapy.

Diabetes Care
Trang T LyTimothy W Jones

Abstract

The advent of sensor-augmented pump therapy with a low-glucose suspend (LGS) function (Medtronic Paradigm Veo System), allowing insulin to be automatically suspended for up to 2 h when sensor glucose falls below a preset threshold, has the potential to reduce the duration of hypoglycemia. In this article, we analyzed blood glucose profiles following a full 2-h insulin suspension activated by the LGS function, as well as examined different patterns of use among patients. Data from a cohort of participants using the Veo System for up to 6 months were analyzed to determine the time and duration of insulin suspension activated by the LGS function. We further evaluated overnight suspend events with no patient response occurring prior to 3:00 a.m., which allowed us to determine the pattern of sensor glucose values with no patient intervention during and after the period of insulin suspension. There were 3,128 LGS events during the 2,493 days evaluated. The median duration was 11.2 min, and 36% of events occurred overnight. There were 126 full 2-h suspend events that occurred overnight with no patient response, occurring before 3:00 a.m. For these events, the mean sensor glucose at the end of the 2-h suspend period was 99 ± 6 mg/dL ([...Continue Reading

References

Jun 6, 1998·The New England Journal of Medicine·T W JonesW V Tamborlane
Aug 13, 2008·Diabetes Care·Bruce BuckinghamFergus Cameron
Oct 17, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Robert J TanenbergAlmond J Drake
Feb 20, 2010·Journal of Diabetes Science and Technology·D Barry KeenanJohn J Mastrototaro
Aug 11, 2011·Diabetes Technology & Therapeutics·Thomas DanneAndreas Thomas
Oct 13, 2011·Diabetes Technology & Therapeutics·Trang T LyAndrew Wilson
Oct 27, 2011·Journal of Diabetes Science and Technology·Pratik AgrawalFrancine R Kaufman

❮ Previous
Next ❯

Citations

Jun 25, 2013·The New England Journal of Medicine·Richard M BergenstalUNKNOWN ASPIRE In-Home Study Group
Mar 28, 2013·International Journal of Pediatric Endocrinology·Noelle S Larson, Jordan E Pinsker
Jan 11, 2014·Diabetes Technology & Therapeutics·Satish K GargFrancine R Kaufman
Apr 23, 2014·Expert Opinion on Drug Delivery·Martin Tauschmann, Roman Hovorka
Jun 8, 2015·Diabetes Care·Bruce A BuckinghamUNKNOWN In Home Closed Loop Study Group
Nov 6, 2015·Industrial & Engineering Chemistry Research·Lauren M HuyettFrancis J Doyle
Jul 6, 2015·Biosensors & Bioelectronics·Anthony G A AggidisGeorge A Aggidis
Apr 23, 2013·Diabetes, Obesity & Metabolism·P A BakhtianiW K Ward
May 9, 2014·Diabetes Care·David M MaahsUNKNOWN In Home Closed Loop Study Group
May 6, 2016·Diabetes Technology & Therapeutics·Mary B AbrahamTimothy W Jones
May 31, 2014·Journal of Diabetes Science and Technology·Volker LodwigLutz Heinemann
May 31, 2014·Journal of Diabetes Science and Technology·Volker LodwigLutz Heinemann
Oct 16, 2013·Journal of Diabetes Science and Technology·Garry M Steil, Gerold M Grodsky
May 19, 2017·Diabetes Technology & Therapeutics·Lenka PetruzelkovaBarbora Obermannova
Dec 27, 2018·Diabetes Technology & Therapeutics·Mary B AbrahamUNKNOWN PLGM Study Group
Feb 22, 2017·Diabetes Technology & Therapeutics·Bruce A BuckinghamFrancine R Kaufman
Nov 13, 2020·Pediatric Diabetes·Kate C VerbeetenUNKNOWN CGM TIME Trial Study Group and the JDRF Canadian Clinical Trials Group

❮ Previous
Next ❯

Software Mentioned

CareLink

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.